The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
NCT04300335 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2025-10-01
Summary
Multiple myeloma is the second most common haematological cancer with a cancer incidence of around 500 new cases in Austria per year . Novel treatment methods have significantly increased the cancer-specific survival rate in patients with multiple myeloma. For Austria, this means that 5- and 10-year survival rates rose from 32.1 to 46.4% and from 19.0 to 25.6% from the end of the 1980s to the end of the 2000s.
Longer survival is associated with the need to maintain independence and quality of life in the longer term. In this context, regular physical training has seen a significant increase in the importance of cancer in recent years.The guidelines of the American College of Sports Medicine still contain very general training recommendations for cancer patients. Either 150 minutes of moderate or 75 minutes of intensive endurance training per week are recommended, supplemented by at least two units of strengthening training and stretching exercises for the large muscle groups.
In a recent cross-sectional and pilot study with multiple myeloma patients that was carried out at the Clinic for Physical Medicine, Rehabilitation and Occupational Medicine at the Medical University of Vienna (EK 1725/2018), it was on the one hand identified that there was a discrepancy between these patients on the one hand has given actual and perceived risk of falling, and on the other hand it is concluded that training recommendations should be carried out separately in group and individual training according to the actual risk of falling and fracture.
The present project is the follow-up to this cross-sectional investigation. The aim is to examine the feasibility and effects of a structured, physical training program carried out over a period of 12 weeks on physical performance, quality of life, body composition and the risk of falling. The effects of patients with increased risk in individual training sessions are compared to those of lower risk patients in group training sessions. Furthermore, the study patients will be able to bring training partners with them to their own training units if available and for their own security. They are evaluated separately according to qualitative criteria.
Conditions
Interventions
- OTHER
-
Individual Exercise
Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise
- OTHER
-
Group Exercise
Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
Sponsors & Collaborators
-
Medical University of Vienna
lead OTHER
Principal Investigators
-
Richard Crevenna, Prof. MD · Medical University of Vienna
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-31
- Primary Completion
- 2026-10-31
- Completion
- 2026-12-31
Countries
- Austria
Study Locations
More Related Trials
-
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
NCT03777306 ·Status: COMPLETED ·Phase: NA
-
Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
NCT04533217 ·Status: RECRUITING ·Phase: NA
-
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
NCT02431208 ·Status: COMPLETED ·Phase: PHASE1
-
Rehabilitation Management for Patients with Multiple Myeloma
NCT06838065 ·Status: COMPLETED
-
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
NCT00205764 ·Status: COMPLETED ·Phase: PHASE3
-
Autologous Transplantation for Multiple Myeloma
NCT00378222 ·Status: COMPLETED ·Phase: PHASE3
-
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
NCT00171925 ·Status: TERMINATED ·Phase: PHASE3
-
Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
NCT01665014 ·Status: UNKNOWN ·Phase: PHASE2
-
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT05675319 ·Status: TERMINATED ·Phase: PHASE3
-
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT02353572 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
NCT04223661 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04445701 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
NCT00036140 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma
NCT00872521 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
NCT00861250 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
NCT06892522 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
NCT01142232 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
NCT01183949 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
NCT06151717 ·Status: COMPLETED
-
Autologous Transplant for Multiple Myeloma
NCT00177047 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
NCT00747123 ·Status: COMPLETED ·Phase: PHASE2
-
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
NCT00366106 ·Status: TERMINATED ·Phase: PHASE2
-
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
NCT00039754 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure
NCT01241396 ·Status: COMPLETED